Has Tia Mowry confirmed using HRT?

No. Mowry has discussed endometriosis and postpartum hormonal struggles publicly but has not confirmed using prescription hormone replacement therapy. Any claims to the contrary are speculation.

What are the most common symptoms after stopping HRT?

Hot flashes, night sweats, mood changes, sleep disruption, and joint pain are the most frequently reported symptoms. A WHI study found over half of women experienced moderate to severe vasomotor symptoms within a year of stopping.

Does tapering HRT reduce rebound symptoms compared to stopping abruptly?

Current evidence suggests no significant difference. A randomized trial comparing gradual taper to abrupt cessation found similar symptom rebound rates in both groups. Tapering may offer psychological comfort, but measurable clinical benefit has not been demonstrated.

Can endometriosis come back after stopping hormonal therapy?

Yes. Symptom recurrence rates range from 40% to 50% within five years of discontinuing hormonal suppression. Continuous oral contraceptive use after surgery has been shown to reduce endometrioma recurrence significantly.

How long is it safe to stay on HRT?

The 2022 Menopause Society position statement moved away from fixed time limits. Continuation is appropriate when benefits outweigh risks, assessed annually. Key monitoring includes breast cancer screening, bone density, cardiovascular risk factors, and symptom evaluation.

Tia Mowry, Maintenance, and What Happens If You Stop

By HealthRX Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

What Tia Mowry Has Said Publicly

Tia Mowry, best known for her role on Sister, Sister and the Cooking Channel's Tia Mowry at Home, has been vocal about two hormonally driven health challenges: endometriosis and difficult postpartum recovery periods after the births of her two children. In interviews and on her social platforms, she has described extreme fatigue, weight fluctuations, and mood disruptions tied to hormonal shifts following pregnancy.

She co-founded the wellness brand Anser, which markets supplements targeting gut health, prenatal nutrition, and hormonal balance. In a 2020 interview with Today, Mowry described feeling "not like myself" in the months after giving birth and credited dietary changes, supplementation, and working with her medical team for her recovery.

It is worth stating clearly: Mowry has not publicly confirmed using prescription HRT, bioidentical hormones, or any specific hormonal medication. Public speculation about her using hormone therapy stems from her openness about hormonal health and her wellness brand's focus on hormone-adjacent products. The HealthRX Medical Team treats this distinction seriously. Everything below addresses the clinical science of HRT discontinuation and maintenance as it applies to women in Mowry's publicly described situation, not as a claim about her private medical choices.

At a glance

Public record: Tia Mowry has discussed endometriosis, postpartum hormonal struggles, and founding a wellness brand. She has not confirmed prescription HRT use.
Clinical question: For women using HRT to manage endometriosis symptoms or perimenopausal/postpartum hormone disruption, what does the evidence say about stopping vs. continuing?
Key finding: Abrupt HRT cessation can trigger vasomotor symptom rebound in up to 50% of women, and endometriosis recurrence rates after discontinuing hormonal suppression range from 40% to 50% within five years.
HealthRX Medical Team position: Discontinuation decisions should be individualized, guided by symptom burden, bone density status, and cardiovascular risk profile.

Endometriosis and Hormonal Management: The Clinical Baseline

Endometriosis affects roughly 10% of reproductive-age women worldwide, according to the World Health Organization. Hormonal therapies remain a cornerstone of medical management. Options include combined oral contraceptives, progestins, GnRH agonists, and GnRH antagonists like elagolix (FDA approval, 2018).

The goal of hormonal therapy in endometriosis is suppression of estrogen-driven tissue growth outside the uterus. A 2014 Cochrane review found that continuous hormonal suppression reduced pain recurrence compared to cyclic regimens. The clinical problem is what happens when therapy stops.

Recurrence data are sobering. A prospective study published in Human Reproduction followed women after discontinuation of GnRH agonist therapy and found symptom recurrence in approximately 50% within 12 months. Post-surgical hormonal maintenance with oral contraceptives reduced recurrence of endometriomas to 8% at 24 months versus 34% in controls, per a 2010 randomized trial.

For a woman like Mowry, who has publicly described years of endometriosis pain before diagnosis, these numbers frame a real clinical tension: stopping hormonal management may mean symptom return, while continuing requires ongoing monitoring.

Postpartum Hormones: The Crash and Recovery Window

Mowry's public descriptions of postpartum difficulty align with a well-documented physiological event. After delivery, estrogen and progesterone levels drop precipitously within 24 to 48 hours from their pregnancy peaks (estradiol can reach 20,000 pg/mL in late pregnancy and fall below 50 pg/mL postpartum).

This hormonal withdrawal is a recognized trigger for mood disorders. The American College of Obstetricians and Gynecologists estimates that postpartum depression affects 1 in 7 women, with hormonal fluctuation playing a contributing role alongside psychosocial stressors.

Prescription HRT in the immediate postpartum period is uncommon. The standard of care for postpartum mood disorders includes SSRIs, psychotherapy, and (since 2023) the oral neurosteroid zuranolone (FDA-approved as Zurzuvae). Brexanolone (Zulresso), an IV formulation, was approved in 2019 for severe cases.

Estrogen supplementation postpartum has been studied but remains off-label for mood indications. A small RCT in the American Journal of Psychiatry found sublingual estradiol improved depressive symptoms in postpartum women compared to placebo, but sample sizes were limited and the approach has not entered mainstream guidelines.

What Happens When You Stop HRT: The Discontinuation Evidence

For women on menopausal HRT (estrogen with or without progestogen), discontinuation has been studied more extensively than for endometriosis-specific regimens. The evidence clusters around three domains.

Vasomotor symptom rebound. A WHI ancillary study found that 55.5% of women who stopped HRT experienced moderate to severe hot flashes within the year after cessation, compared to 21.2% of women who had been on placebo. Gradual tapering has intuitive appeal, but a randomized trial comparing abrupt versus tapered discontinuation found no significant difference in symptom severity or duration. Both groups experienced rebound. The symptoms typically peak within three to six months and gradually diminish, though a subset of women report persistent vasomotor symptoms for years.

Bone density loss. Estrogen is the primary hormonal regulator of bone remodeling in women. Stopping HRT leads to accelerated bone loss at rates comparable to early menopause, approximately 2% to 4% per year at the spine in the first two years after cessation. The Women's Health Initiative demonstrated that the bone-protective effects of HRT do not persist after discontinuation. For women with low bone density at baseline, stopping HRT without transitioning to another antiresorptive agent (bisphosphonates, denosumab) creates measurable fracture risk.

Cardiovascular considerations. The timing hypothesis, supported by data from the WHI age-stratified analyses, suggests that HRT initiated within 10 years of menopause may confer cardiovascular benefit, while later initiation may increase risk. On discontinuation, observational data from a Finnish registry study showed a transient increase in cardiac events in the first year after stopping HRT, particularly in women over 60. This finding has not been replicated in randomized trials, so the HealthRX Medical Team considers it hypothesis-generating rather than definitive.

When Staying On Makes Clinical Sense

The 2022 Menopause Society position statement (formerly NAMS) moved away from arbitrary duration limits for HRT. The updated guidance recommends individualized continuation based on the benefit-risk profile for each patient. Women with persistent vasomotor symptoms, those at elevated fracture risk without alternative bone protection, and those using hormonal suppression for endometriosis or other estrogen-dependent conditions may reasonably continue therapy with periodic reassessment.

Long-term safety monitoring includes annual breast cancer risk evaluation (mammography per USPSTF guidelines), periodic bone density assessment via DEXA, cardiovascular risk factor review, and symptom reassessment.

For endometriosis specifically, the European Society of Human Reproduction and Embryology guidelines recommend that hormonal treatment be considered long-term when surgery is not desired or has already been performed, since recurrence rates without suppression remain high.

The HealthRX Medical Team Take

Mowry's public story puts a recognizable face on two distinct but overlapping hormonal challenges: endometriosis (a chronic, estrogen-dependent condition with high recurrence) and postpartum hormonal disruption (an acute, self-limited physiological event with mood and metabolic consequences).

Whether or not Mowry has used prescription HRT is her private medical information, and we do not speculate beyond what she has shared publicly. What we can say is this: for any woman managing endometriosis who is weighing whether to stop hormonal therapy, the recurrence data argue strongly for continued suppression unless there is a specific reason to discontinue (pregnancy planning, intolerable side effects, or a shift in risk profile). Abrupt stops tend to bring symptoms back. Gradual tapering does not reliably prevent this.

For postpartum hormonal recovery, the evidence supports time, targeted pharmacotherapy for mood symptoms when indicated, and close follow-up. Supplemental estrogen in the postpartum window remains investigational for mood indications and should only be considered under direct medical supervision.

The HealthRX Medical Team encourages women in similar situations to request hormone panels (estradiol, FSH, progesterone, DHEA-S, thyroid function) at baseline and during any transition off hormonal therapy. Data-driven decision-making reduces the guesswork that too often accompanies these conversations.

Frequently asked questions

›